Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL), Carbonite (CARB), and Check Point (CHKP) downgraded to Hold from Buy at Jefferies. 2. TerraForm Power (TERP) downgraded to Equal Weight from Overweight at Barclays. 3. Puma Biotechnology (PBYI) downgraded to Sell from Neutral at Goldman Sachs while Nektar Therapeutics (NKTR) was double downgraded to Sell from Buy. 4. Qiagen (QGEN) downgraded to Underweight from Neutral at JPMorgan and to Equal Weight from Overweight at Barclays. 5. Helmerich & Payne (HP) and Patterson-UTI (PTEN) downgraded to Neutral from Buy at BofA/Merrill. Nine Energy Services (NINE) and FTS International (FTSI) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Vertex (VERX) announced that it has been selected to join the Oracle Independent Software Vendor, ISV, Accelerator for SaaS Initiative. With expertise in Oracle (ORCL) Cloud Fusion Cloud Applications integrations, Vertex continues to leverage the power of contract and tax data to optimize customer operations and outcomes. "Building on our longstanding relationship with Oracle, we are thrilled to join the Oracle ISV Accelerator," said Bradd Wildstein, Vice President, Indirect Sales at Vertex, Inc. "Through this partnership, Vertex can now enhance our customers' finance and sales processes by integrating essential tax solutions into Oracle Fusion Applications. It's more than just data integration - it's about unifying disparate functions, streamlining operations, and amplifying benefits for our mutual customers."

Biolojic Design announced that Nektar exercised its license option to develop a program resulting from the companies' research collaboration initiated in 2021. The research collaboration was established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II, a novel, biologically-validated disease target implicated in a wide range of autoimmune diseases that has been difficult to drug with conventional medicines. The antibody program selected for development is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021 research agreement, Nektar has tested antibodies computationally designed by Biolojic Design to precisely agonize the TNFR2 receptor. Following successful preclinical in vitro and in vivo studies, Nektar decided to exercise the license option and has been advancing the program through IND enabling studies since late December, 2023. If the NKTR-0165 candidate proceeds through clinical development, Biolojic Design is entitled to development milestones and sales royalties.

Oracle Chairman Larry Ellison said the company is moving its world headquarters to Nashville, Tennessee, Ashley Capoot of CNBC reports. Ellison said Oracle is moving to a "huge campus" and it is closer to "the center of the industry we're most concerned about, which is the health-care industry." Reference Link